大冢制药（4568.T）股价与投研分析
Otsuka Holdings · 日本市场 · 医药健康
关键指标
- 最新价
- JPY 2887.00
- 日内涨跌
- -6.21%
- 市值
- JPY 5.26 万亿
- 市盈率 TTM
- 17.83
- 市净率
- 2.99
- 52 周最高
- JPY 3913.00
- 52 周最低
- JPY 2390.00
- 股息率
- 3.44%
- 成交量
- 股 288.46 万
- 上市市场
- 日本
公司概况
大冢制药（英文名 Otsuka Holdings，股票代码 4568.T）在日本市场上市， 属于医药健康行业，当前处于成熟阶段。核心标签：制药、精神类药物、营养品。
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally. The company offers Enhertu for the treatment of HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule for colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3, as well as symptomatic TGCT; Vanflyta, a FLT3 inhibitor for the treatment of acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency; and Datroway for the treatment of HR positive and HER2 negative breast cancer, as well as NSCLC. It also provides Lixiana and Savaysa, which are direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT, which are antihypertensive agents; Nilemdo that lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe that reduces cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgality for the treatment of migraine attacks; Pralia for the treatment of osteoporosis and bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications and GCTB; Tarlige for the treatment of neuropathic pain; Venofer for the treatment of iron deficiency anemia; Vimpat, an anti-seizure medication; and Reyvow for the treatment of acute migraine attacks. Further, it provides Daichirona, a coronavirus RNA vaccine; Flumist, an intranasal live attenuated influenza vaccine; adsorbed cell culture-derived influenza vaccine; measles rubella combined vaccine; and mump vaccine. The company was formerly known as Sankyo Co. Ltd. and changed its name to Daiichi Sankyo Company, Limited in September 2005. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Chuo, Japan.
AI 三层投研框架
- 宏观周期层：利率、通胀、汇率与流动性如何影响日本市场的估值中枢。
- 行业格局层：用 PEST、波特五力与产业链位置判断医药健康行业的利润分配。
- 公司质地层：把 大冢制药 的增速、利润率、ROE 与现金流放进同行业横向对比。
需要完整报告？回到终端 可基于真实财报数据生成三层 AI 分析。